CollPlant Biotechnologies (CLGN) Short term Debt (2019 - 2020)
CollPlant Biotechnologies' (CLGN) quarterly Short term Debt came in at $12000.0 in Q2 2020, down 50.0% on a QoQ basis from $24000.0 in Q4 2019.
CollPlant Biotechnologies (CLGN) Short term Debt (2019 - 2020) Analysis & Trends
CollPlant Biotechnologies (CLGN) has 2 years of Short term Debt data on file, last reported at $12000.0 in Q2 2020.
- Quarterly Short term Debt changed N/A year-over-year to $12000.0 in Q2 2020, while the trailing twelve-month figure through Jun 2020 was $12000.0 (changed N/A YoY) and the FY2019 annual result came in at $24000.0, changed N/A from the prior year.
- Short term Debt retreated to $12000.0 in Q2 2020, from $24000.0 in the prior quarter.
- In the past five years, Short term Debt ranged from a high of $24000.0 in Q4 2019 to a low of $12000.0 in Q2 2020.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 140.00 Bn | 132.14 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 86.31 Bn | 78.32 Bn | 3.93 Bn |
| 3 | Argenx Se | 65.24 Bn | 60.06 Bn | 1.37 Bn |
| 4 | Moderna | 62.41 Bn | 57.27 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 42.25 Bn | 37.15 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.18 Bn | 27.88 Bn | 992.69 Mn |
| 7 | BioNTech SE | 28.93 Bn | 10.54 Bn | 668.28 Mn |
| 8 | Insmed | 27.55 Bn | 26.39 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.28 Bn | 26.44 Bn | - |
| 10 | CollPlant Biotechnologies | 4.13 Mn | 4.13 Mn | -243,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2020 | 6,000.00 |
| Jun 30, 2020 | 12,000.00 |
| Dec 31, 2019 | 24,000.00 |